Telix Pharmaceuticals (TLX) Competitors $16.12 -0.38 (-2.28%) As of 07/3/2025 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock TLX vs. TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, and BPMCShould you be buying Telix Pharmaceuticals stock or one of its competitors? The main competitors of Telix Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Telix Pharmaceuticals vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Telix Pharmaceuticals (NASDAQ:TLX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk. Which has stronger valuation and earnings, TLX or TEVA? Telix Pharmaceuticals has higher earnings, but lower revenue than Teva Pharmaceutical Industries. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals$516.72M10.56$32.93MN/AN/ATeva Pharmaceutical Industries$16.54B1.18-$1.64B-$1.15-14.83 Do institutionals & insiders have more ownership in TLX or TEVA? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer TLX or TEVA? In the previous week, Teva Pharmaceutical Industries had 5 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 13 mentions for Teva Pharmaceutical Industries and 8 mentions for Telix Pharmaceuticals. Teva Pharmaceutical Industries' average media sentiment score of 1.15 beat Telix Pharmaceuticals' score of 0.67 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend TLX or TEVA? Telix Pharmaceuticals presently has a consensus target price of $22.33, indicating a potential upside of 38.51%. Teva Pharmaceutical Industries has a consensus target price of $24.13, indicating a potential upside of 41.50%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Telix Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Is TLX or TEVA more profitable? Telix Pharmaceuticals has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Telix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telix PharmaceuticalsN/A N/A N/A Teva Pharmaceutical Industries -7.74%45.44%6.95% SummaryTeva Pharmaceutical Industries beats Telix Pharmaceuticals on 11 of the 14 factors compared between the two stocks. Get Telix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLX vs. The Competition Export to ExcelMetricTelix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.44B$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E RatioN/A21.5627.5220.22Price / Sales10.56281.76421.02118.64Price / Cash140.7342.7336.8958.07Price / Book14.407.518.045.67Net Income$32.93M-$55.05M$3.18B$249.13M7 Day Performance0.77%4.61%2.90%3.28%1 Month Performance-7.12%4.72%3.70%5.55%1 Year PerformanceN/A5.92%36.15%21.12% Telix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLXTelix PharmaceuticalsN/A$16.12-2.3%$22.33+38.5%N/A$5.44B$516.72M0.00N/ANews CoverageAnalyst ForecastGap DownTEVATeva Pharmaceutical Industries4.2262 of 5 stars$16.96+0.1%$24.44+44.1%+1.4%$19.44B$16.54B-14.7536,830SMMTSummit Therapeutics2.528 of 5 stars$20.39-0.8%$35.09+72.1%+253.3%$15.27B$700K-59.97110Trending NewsAnalyst ForecastOptions VolumeITCIIntra-Cellular Therapies0.982 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.5747 of 5 stars$20.68-2.3%$39.17+89.4%-18.8%$13.57B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories2.8117 of 5 stars$15.31+0.5%$16.95+10.7%-0.9%$12.71B$3.81B23.2027,811ASNDAscendis Pharma A/S3.6664 of 5 stars$175.78-0.6%$220.67+25.5%+29.7%$10.81B$393.54M-27.991,017Analyst ForecastVTRSViatris3.307 of 5 stars$8.85-0.2%$10.40+17.5%-10.9%$10.41B$14.74B-2.7932,000QGENQiagen4.0422 of 5 stars$46.72-0.1%$47.74+2.2%+22.5%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3794 of 5 stars$25.67-0.9%$46.61+81.6%-73.7%$10.02B$3.24B-2.945,800Options VolumeBPMCBlueprint Medicines1.5716 of 5 stars$128.40+0.2%$128.06-0.3%+17.6%$8.28B$508.82M-51.98640High Trading Volume Related Companies and Tools Related Companies TEVA Alternatives SMMT Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives MRNA Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
